Medical network on July 18 - from the point of sample hospital market performance, about 20% of the drug sales has been in previous years of growth slowing to around 10%. Samples of domestic hospital, according to data from PDB samples hospital overall market from $2005 in 32.69 billion, rising to $2016 in 166.15 billion, 2005-2016 annual compound growth rate of 16.9%.
Sample hospital sales and growth in 2005-2016 (unit: one hundred million yuan)
In 2016, 10 samples of hospital treatment areas occupy 87.2% of the overall market, faster-growing have antitumor medicine and respiratory system drugs, growth exceeded 10.0%. In 10 major therapeutic areas, there are seven areas of the overall market has more than 10 billion yuan, this article will analysis the focus in the field of treatment for the product in turn.
1. The anti-infective drugs, 25.1 billion yuan
Year-on-year growth: 7.9% in 2016
CAGR (2005-2016) : 10.3%
Notable products: entecavir, America e.faecalis, voriconazole, moxifloxacin, piperacillin/triazole temple, cefoperazone/shu ba jotham, cefoperazone/he thiazole temple, oxygen cephalosporins
Samples of domestic hospitals, according to the domestic anti-infection drugs market size increased from 2005, 8.52 billion yuan in 2016 to 25.1 billion yuan, 2005-2016 annual compound growth rate of 10.3%.
According to statistics, anti-infection products involving 279, 2016 samples of hospital before 50 drug purchasing medicine amount is 22 billion yuan, 87.4% of the overall market. Among them, the sample hospitals in the top 10 products: entecavir, America e.faecalis, voriconazole, moxifloxacin, piperacillin/he azole temple, cefoperazone/shu ba jotham, levofloxacin, imine south/west he ding, cefoperazone/he thiazole temple, oxygen cephalosporins. The top 10 products sales amounted to 9.75 billion yuan, 38.8% of the overall market.
Anti-infective drugs faster-growing products are: entecavir sales of 1.71 billion yuan, a 16.2% increase from the same period. Beauty e.faecalis sales of 1.37 billion yuan, a 20.5% increase from the same period. Voriconazole sales of 1.2 billion yuan, a 13.4% increase from the same period. Moxifloxacin sales of 910 million yuan, a 26.5% increase from the same period. Piperacillin/he thiazole ba sales of 890 million yuan, a 12.8% increase from the same period. Cefoperazone/he thiazole ba sales of 730 million yuan, a 11.2% increase from the same period. Cefepime oxygen generated sales of around 660 million yuan, a 28.7% increase from the same period. The product growth exceeded 10.0%, pulling the anti-infective class overall market growth.
2. The cardiovascular system is 19.97 billion yuan
Year-on-year growth: 4.7% in 2016
CAGR (2005-2016) : 14.6%
Notable products: atorvastatin statin, rui shu
Samples of domestic hospitals, according to the domestic cardiovascular system medicine market size increased from 2005, 4.44 billion yuan in 2016 to 19.97 billion yuan, 2005-2016 annual compound growth rate of 14.6%.
According to statistics, cardiovascular system drug products involving 251, 2016, 50 before sample hospital drug purchasing medicine amount is 17.17 billion yuan, 86.0% of the overall market. Among them, the sample hospitals in the top 10 products: atorvastatin, lead to, creatine phosphate, coenzyme A/coenzyme of I, shu laval statin, amlodipine, cassia pp qi/salvia miltiorrhiza and ligustrazine, refreshing static injection and nifedipine. The top 10 products sales amounted to 9.36 billion yuan, 46.9% of the overall market.
Cardiovascular system medicine faster-growing products are: atorvastatin sales of 1.58 billion yuan, a 10.1% increase from the same period. Rui shu laval statin sales of 1.37 billion yuan, a 10.0% increase from the same period. In the field of cardiovascular system medicine, faster-growing both products for the cholesterol-lowering drugs, highlights the statin main position in the field.
Blood and hematopoietic system 3. 18.51 billion yuan
Year-on-year growth: 9.5% in 2016
CAGR (2005-2016) : 16.2%
Notable products: human blood albumin
Blood samples of domestic hospitals, according to domestic and hematopoietic system medicine market size increased from 2005, 3.55 billion yuan in 2016 to 18.51 billion yuan, 2005-2016 annual compound growth rate of 16.2%.
According to statistics, 2016 blood and hematopoietic system drug products involving 136 sample hospitals before 50 drug purchasing medicine amount is 17.43 billion yuan, 94.2% of the overall market. Among them, the sample hospitals in the top 10 products: human blood albumin, sodium chloride, clopidogrel, compound amino acid, invert sugar, blood clotting enzyme, propylene ammonia acyl glutamine, fat milk, glucose, cobalt amine. The top 10 products sales amounted to 11.59 billion yuan, 62.6% of the overall market.
Blood and hematopoietic system medicine faster-growing products are: human blood albumin sales of 2.31 billion yuan, a 14.6% increase from the same period. In the field of blood and hematopoietic system drugs, only this one product is growing rapidly, the growth rate of more than 10.0%.
4. Antitumor medicine 16.98 billion yuan
Year-on-year growth: 11.2% in 2016
CAGR (2005-2016) : 19.6%
Notable products: pemetrexed, oxaliplatin into, for gonow, capecitabine, li injection, for mo thiazole amine
Samples of domestic hospitals, according to the domestic anti-tumor medicine market size increased from 2005, 2.38 billion yuan in 2016 to 16.98 billion yuan, 2005-2016 annual compound growth rate of 19.6%.
According to statistics, anti-tumor medicine products involving 135, 2016 samples of hospital before 50 drug purchasing medicine amount is 9.57 billion yuan, 62.7% of the overall market. Among them, the sample hospitals in the top 10 products: paclitaxel, pemetrexed, west he sai, oxaliplatin into, for more, capecitabine, li injection, imatinib, gemcitabine, on behalf of thiazole amine. The top 10 products sales amounted to 8.54 billion yuan, 50.3% of the overall market.
Faster-growing antitumor drug products are: pemetrexed sales of 1.11 billion yuan, a 10.5% increase from the same period. Oxaliplatin into sales of 910 million yuan, a 17.3% increase from the same period. Gonow for sales of 840 million yuan, a 17.3% increase from the same period. Capecitabine sales of 740 million yuan, a 12.4% increase from the same period. Li injection sales of 690 million yuan, a 15.9% increase from the same period. For the mo thiazole amine sales of 480 million yuan, a 20.1% increase from the same period. Is the above six product grew by more than 10.0% of products, including, for gonow, for mo thiazole amine oxaliplatin into three products rose by more than 15.0%, the market performance is more outstanding.
5. The nervous system drugs, 15.17 billion yuan
Year-on-year growth: 9.7% in 2016
CAGR (2005-2016) : 22.7%
Notable products: mouse nerve growth factor, with sheen, pursuant to the adr, butyl phthalide
Samples of domestic hospitals, according to the domestic nervous system drugs market size increased from 2005, 1.6 billion yuan in 2016 to 15.17 billion yuan, 2005-2016 annual compound growth rate of 22.7%.
According to the statistics, nervous system drugs products involving 147, 2016, 50 before sample hospital drug purchasing medicine amount is 14.59 billion yuan, accounting for 95.2% of the overall market. Among them, the sample hospitals in the top 10 products: ganglioside, olathe, mouse nerve growth factor, with sheen, calf blood to protein extract, pursuant to the adr, brain glycosides carnosine, ginkgo biloba, butyl phthalide, vinpocetine. The top 10 products sales amounted to 9.76 billion yuan, 54.0% of the overall market.
Nervous system drugs faster-growing products: mouse nerve growth factor generated sales of 1.13 billion yuan, a 17.0% increase from the same period. To assist sales of 1.01 billion yuan, a 27.0% increase from the same period. The adr in sales of 770 million yuan, a 16.1% increase from the same period. Butyl phthalide sales of 690 million yuan, a 27.8% increase from the same period. The above four product growth by more than 10.0%, of which, with sheen, butyl phthalide market performance is more outstanding, the growth rate of close to 30.0%.
6. The digestive system drugs, 14.14 billion yuan
Year-on-year growth: 8.2% in 2016
CAGR (2005-2016) : 17.0%
Notable products: rabeprazole azole, glycyrrhizic acid magnesium, SiQiong parlour
Samples of domestic hospitals, according to the domestic digestive system drugs market size increased from 2005, 2.5 billion yuan in 2016 to 14.14 billion yuan, 2005-2016 annual compound growth rate of 17.0%.
According to statistics, in 2016, the digestive system drugs drug products involving 266, top 50 samples hospital drug purchasing medicine amount is 12.86 billion yuan, 91.0% of the overall market. Among them, the sample hospitals in the top 10 products: LAN sola, panxi tora etc, omeprazole, esso beauty pull azole, rabeprazole azole, glycyrrhizic acid magnesium, l-carnitine, and ray parlour SiQiong, tropane SiQiong, compound glycyrrhizin. The top 10 products sales amounted to 8.18 billion yuan, 57.8% of the overall market.
The digestive system drugs faster-growing products are: rabeprazole azole sales of 760 million yuan, a 43.6% increase from the same period. Glycyrrhizic acid magnesium sales of 1.22 billion yuan, a 27.0% increase from the same period. Ray parlour SiQiong generated sales of 630 million yuan, a 17.2% increase from the same period. Growth are the above three products by more than 10.0%, of which, rabeprazole azole growth rate more than 40.0%.
7. The immune modulators of 12.65 billion yuan
Year-on-year growth: 7.5% in 2016
CAGR (2005-2016) : 15.6%
Notable products: uct alpha 1, human immunoglobulin, tacrolimus, spleen ammonia peptide, RNA
Samples of domestic hospitals, according to the domestic immune regulator market size increased from 2005, 2.56 billion yuan in 2016 to 12.65 billion yuan, 2005-2016 annual compound growth rate of 15.6%.
According to statistics, in 2016 the immune modulators drug products involved in 66. Among them, the sample hospitals in the top 10 products are: 1, thymopentin uct alpha, immunoglobulin, Kang Yi injection, tacrolimus, recombinant human granulocyte stimulating factor, spleen, ribonucleic acid, ammonia peptide? For he phenol ester, ginseng and astragalus centralizer injection. The top 10 drug purchasing medicine amount is 8.16 billion yuan, 64.5% of the overall market.
Immune modulators faster-growing products are: uct alpha 1 sales of 1.97 billion yuan, a 12.1% increase from the same period. People immunoglobulin sales of 1.04 billion yuan, a 27.0% increase from the same period. Tacrolimus sales of 750 million yuan, a 10.4% increase from the same period. Spleen ammonia peptide sales of 690 million yuan, a 21.9% increase from the same period. RNA generated sales of 680 million yuan, a 14.8% increase from the same period. Both the above five products by more than 10.0%, of which, immunoglobulin growth rate of nearly 30.0%.
Conclusion the < < <
Whole, starting in 2015, the pharmaceutical industry into the optimized adjustment, improve the concentration ratio of pharmaceutical enterprises in China in 2016, competitive advantage and superior enterprises to advantage area and China prescription drug market opportunities and challenges.
With national policy intensive distribution, bidding, and in 2017 the new health care, negotiation directory, such as policy gradually fall to the ground, the pharmaceutical industry is in the right direction. Around the policy implementation has important effect on the prescription drugs market effect, drug firms need to fully grasp the policy execution, formulate reasonable prescription channel strategy, this will help to match the medicine adjust strategic direction, looking for new growth point of prescription drug sales. |
